Future research might focus on youth in clinical settings and target symptoms of psychopathology.
Borderline personality is a complex disorder and pharmacological intervention is typically focused on target symptoms.
This article describes the results of recent medication trials designed to target symptoms associated with FraX.
Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation.
The assessment of Quality of Life (QoL) is an important tool for elucidating target symptoms that are particularly bothersome to patients.
For these exploratory analyses, p < .05 was utilized as the critical alpha to identify target symptoms of interest for future investigation of this intervention, recognizing the multiple testing might increase our type I error.
There were no statistically significant differences in patient age, sex, performance status, target symptoms, or classes and initial dose of sedative medications between the patients with adequate and inadequate symptom relief.
To learn more about the progression of HD and the onset of symptoms, click here Traditional pharmaceutical companies often develop treatments by modifying a relatively small number of existing drugs to target symptoms that are common in a number of different diseases.
Psychosis accounted for 5% of the target symptoms.
Top target symptoms were aggression (48%), irritability (19%), and impulsivity (11%).
The target symptoms were fatigue (61%), breathlessness (16%), generalized weakness (12%), dizziness (6%), or other (5%).
